Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4) - The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects - The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Toll Like Receptor 4 (hToll or CD284 or TLR4) Overview 10 Therapeutics Development 11 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Stage of Development 11 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Therapy Area 12 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Indication 13 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Products Glance 16 Late Stage Products 16 Early Stage Products 17 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Companies 18 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Products under Development by Universities/Institutes 23 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment 25 Assessment by Monotherapy/Combination Products 25 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development 32 Batu Biologics Inc 32 BioLineRx Ltd 33 Biomedica Management Corp 34 eTheRNA Immunotherapies NV 35 Formune SL 36 GlaxoSmithKline Plc 37 Harbor Therapeutics Inc 38 Immune Design Corp 39 Immunovo BV 40 Kyorin Pharmaceutical Co Ltd 41 NovImmune SA 42 Reliance Life Sciences Pvt Ltd 43 TaiwanJ Pharmaceuticals Co Ltd 44 Vascular Biogenics Ltd 45 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles 46 ApTLR-4FT - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 BL-1110 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 C-34 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 CRX-526 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 DMT-210 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 EDA-HPVE7 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 EDA-NS3 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 EDA-TRP2 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 EDAGP-120 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 G-100 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Glyco-23 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 GSK-1795091 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 HE-3286 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 hp-91 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 ibudilast - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 ISAS-01 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 JKB-117 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 JKB-119 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 JKB-121 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 naltrexone hydrochloride - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 NI-0101 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 P-13 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 P-16 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 P-7 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 P-MAPA - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 PEPA-10 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 RSCL-0520 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 RSCL-0521 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 TWJ-201 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 VB-201 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 VB-703 - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Projects 97 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products 102 Toll Like Receptor 4 (hToll or CD284 or TLR4) - Featured News & Press Releases 103 Dec 09, 2016: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland 103 Dec 05, 2016: Immune Design Provides Update on Discovery Platform G100 For Intratumoral Immunotherapy 104 Nov 17, 2016: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study 104 Nov 10, 2016: MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis 105 Oct 30, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland 105 Oct 11, 2016: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis 106 Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 106 Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS 107 Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 108 Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate G100 At ASCO 108 May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 109 May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 110 Apr 21, 2016: Immune Design Announces Presentations on G-100 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 110 Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada 111 Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016 112 Appendix 114 Methodology 114 Coverage 114 Secondary Research 114 Primary Research 114 Expert Panel Validation 114 Contact Us 114 Disclaimer 115
List of Tables Number of Products under Development for, H2 2016 11 Number of Products under Development by Therapy Area, H2 2016 12 Number of Products under Development by Indication, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Early Stage Products, H2 2016 17 Number of Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Development by Companies, H2 2016 (Contd..2) 21 Products under Development by Companies, H2 2016 (Contd..3) 22 Number of Products under Investigation by Universities/Institutes, H2 2016 23 Products under Investigation by Universities/Institutes, H2 2016 24 Assessment by Monotherapy/Combination Products, H2 2016 25 Number of Products by Stage and Mechanism of Action, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Pipeline by Batu Biologics Inc, H2 2016 32 Pipeline by BioLineRx Ltd, H2 2016 33 Pipeline by Biomedica Management Corp, H2 2016 34 Pipeline by eTheRNA Immunotherapies NV, H2 2016 35 Pipeline by Formune SL, H2 2016 36 Pipeline by GlaxoSmithKline Plc, H2 2016 37 Pipeline by Harbor Therapeutics Inc, H2 2016 38 Pipeline by Immune Design Corp, H2 2016 39 Pipeline by Immunovo BV, H2 2016 40 Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 41 Pipeline by NovImmune SA, H2 2016 42 Pipeline by Reliance Life Sciences Pvt Ltd, H2 2016 43 Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2016 44 Pipeline by Vascular Biogenics Ltd, H2 2016 45 Dormant Projects, H2 2016 97 Dormant Projects (Contd..1), H2 2016 98 Dormant Projects (Contd..2), H2 2016 99 Dormant Projects (Contd..3), H2 2016 100 Dormant Projects (Contd..4), H2 2016 101 Discontinued Products, H2 2016 102
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
